Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
- 12 May 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (10), 2520-2533
- https://doi.org/10.1158/1078-0432.ccr-15-1925
Abstract
Purpose:Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants the development of new strategies to improve overall patient survival. Among them, HSP90 is a molecular chaperone involved in the maturation and stability of various oncogenic proteins leading to tumor cells survival and disease progression. We assessed the antitumor properties of a synthetic HSP90 inhibitor, PF4942847, alone or in combination with zoledronic acid in osteosarcoma. Experimental Design:The effects of PF4942847 were evaluated on human osteosarcoma cells growth and apoptosis. Signaling pathways were analyzed by western blotting. The consequence of HSP90 therapy combined or not with zoledronic acid was evaluated in mice bearing HOS-MNNG xenografts on tumor growth, associated-bone-lesions and pulmonary metastasis. The effect of PF4942847 on osteoclastogenesis was assessed on human CD14+ monocytes. Results:In osteosarcoma cell lines, PF4942847 inhibited cell growth in a dose-dependent manner (IC50 ±50nM) and induced apoptosis with an increase of sub-G1 fraction and cleaved-PARP. These biologic events were accompanied by decreased expression of Akt, p-ERK, C-Met and C-RAF1. When administered orally to mice bearing osteosarcoma tumors, PF4942847 significantly inhibited tumor growth by 80%, prolonged survival compared to controls, and inhibited pulmonary metastasis by blocking c-Met, FAK and MMP9 signaling. In contrast to 17-AAG, PF4942847 didn't induce osteoclast differentiation, and synergistically acted with zoledronic acid to delay osteosarcoma progression and prevent bone lesions. Conclusions:All these data provide a strong rationale for clinical evaluation of PF4942847 alone or in combination with zoledronic acid in osteosarcoma.Keywords
Other Versions
This publication has 41 references indexed in Scilit:
- High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric CancerPLOS ONE, 2013
- Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90Clinical Cancer Research, 2011
- A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits OsteoclastogenesisClinical Cancer Research, 2011
- Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in boneProceedings of the National Academy of Sciences of the United States of America, 2008
- Risks and benefits of bisphosphonatesBritish Journal of Cancer, 2008
- Drugging the Cancer Chaperone HSP90Annals of the New York Academy of Sciences, 2007
- Zoledronic Acid Activates the DNA S-Phase Checkpoint and Induces Osteosarcoma Cell Death Characterized by Apoptosis-Inducing Factor and Endonuclease-G Translocation Independently of p53 and Retinoblastoma StatusPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2006
- Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcomaBone, 2005
- Bisphosphonates: new therapeutic agents for the treatment of bone tumorsTrends in Molecular Medicine, 2004
- Met oncogene aberrant expression in canine osteosarcomaJournal of Orthopaedic Research, 2000